Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor.

We have investigated the binding site of the subtype specific antagonist SR 144528, (N-[(1S)-endo-1,3,3-trimethyl bicyclo [2.2. 1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methoxybenzyl)- pyrazo le-3-carboxamide) on the human cannabinoid CB(2) receptor based on functional studies with mutated receptors. Two serine residues in the fourth transmembrane region, Ser(161) and Ser(165), were singly mutated to the cognate cannabinoid CB(1) receptor residue, alanine, and each gave receptors with wild-type properties for the cannabinoid agonists CP 55,940 (1R,3R,4R)-3-[2-hydroxy-4-(1, 1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol) and WIN 55212-2 (R)-(+)[2, 3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl](1-naphthalenyl) methanone, which SR 144528 completely failed to antagonise. Molecular modelling studies show that SR 144528 interacts with residues in transmembrane domains 3, 4, and 5 of the cannabinoid CB(2) receptor through a combination of hydrogen bonds and aromatic and hydrophobic interactions. In addition, the replacement by serine of a nearby cannabinoid CB(2) receptor-specific residue, Cys(175) resulted in wild-type receptor properties with CP 55,940, loss of SR 144528 binding and eight-fold reduced binding and activity of WIN 55212-2, a result compatible with a recently-proposed binding site model for WIN 55212-2.

[1]  P. Kitabgi,et al.  Mutagenesis and Modeling of the Neurotensin Receptor NTR1 , 1998, The Journal of Biological Chemistry.

[2]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[3]  P. Casellas,et al.  SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.

[4]  P. Casellas,et al.  Characterization of two cloned human CB1 cannabinoid receptor isoforms. , 1996, The Journal of pharmacology and experimental therapeutics.

[5]  S. Galiègue,et al.  Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. , 1995, European journal of biochemistry.

[6]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[7]  T. Bonner,et al.  A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. , 1996, Molecular pharmacology.

[8]  R. Pertwee.  Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.

[9]  D. R. Compton,et al.  Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. , 1996, The Journal of pharmacology and experimental therapeutics.

[10]  C. Reynolds,et al.  A new approach to docking in the beta 2-adrenergic receptor that exploits the domain structure of G-protein-coupled receptors. , 1997, Journal of medicinal chemistry.

[11]  T. Werge,et al.  Gly166 in the NK1 receptor regulates tachykinin selectivity and receptor conformation 1 , 1997, FEBS letters.

[12]  C. Strader,et al.  Structure and function of G protein-coupled receptors. , 1994, Annual review of biochemistry.

[13]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[14]  G. Schertler,et al.  Characterisation of an improved two-dimensional p22121 crystal from bovine rhodopsin. , 1998, Journal of molecular biology.

[15]  Patricia H. Reggio,et al.  The Difference between the CB1 and CB2Cannabinoid Receptors at Position 5.46 Is Crucial for the Selectivity of WIN55212-2 for CB2 , 1999 .

[16]  Pascual Ferrara,et al.  Structural Features of the Central Cannabinoid CB1 Receptor Involved in the Binding of the Specific CB1 Antagonist SR 141716A (*) , 1996, The Journal of Biological Chemistry.

[17]  G Vriend,et al.  WHAT IF: a molecular modeling and drug design program. , 1990, Journal of molecular graphics.

[18]  P. Soubrié,et al.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.

[19]  J. Andreassi,et al.  Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity. , 1999, Molecular pharmacology.

[20]  Gert Vriend,et al.  A common motif in G-protein-coupled seven transmembrane helix receptors , 1993, J. Comput. Aided Mol. Des..

[21]  P. Ferrara,et al.  Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. , 1996, Biochimica et biophysica acta.

[22]  G Vassart,et al.  Molecular cloning of a human cannabinoid receptor which is also expressed in testis. , 1991, The Biochemical journal.

[23]  P. Casellas,et al.  A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1 , 1997, The Journal of Biological Chemistry.

[24]  E. Zaki,et al.  Investigation of the Extracellular Accessibility of the Connecting Loop between Membrane Domains I and II of the Bradykinin B2 Receptor* , 1999, The Journal of Biological Chemistry.

[25]  J. Wess,et al.  Conserved Extracellular Cysteine Pair in the M3 Muscarinic Acetylcholine Receptor Is Essential for Proper Receptor Cell Surface Localization but Not for G Protein Coupling , 1999, Journal of neurochemistry.

[26]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[27]  P. Ferrara,et al.  Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor. , 1999, European journal of pharmacology.

[28]  J. Wess,et al.  Identification and Molecular Characterization of m3 Muscarinic Receptor Dimers* , 1999, The Journal of Biological Chemistry.

[29]  P. Casellas,et al.  Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. , 1999, Life sciences.